Jazz Pharmaceuticals (JAZZ) Leases (2016 - 2025)
Historic Leases for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to $61.2 million.
- Jazz Pharmaceuticals' Leases fell 2068.32% to $61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year decrease of 2068.32%. This contributed to the annual value of $53.6 million for FY2024, which is 1799.51% down from last year.
- As of Q3 2025, Jazz Pharmaceuticals' Leases stood at $61.2 million, which was down 2068.32% from $63.1 million recorded in Q2 2025.
- Jazz Pharmaceuticals' 5-year Leases high stood at $149.3 million for Q2 2021, and its period low was $49.2 million during Q1 2025.
- For the 5-year period, Jazz Pharmaceuticals' Leases averaged around $77.6 million, with its median value being $73.3 million (2022).
- As far as peak fluctuations go, Jazz Pharmaceuticals' Leases crashed by 4749.55% in 2022, and later skyrocketed by 1864.45% in 2024.
- Over the past 5 years, Jazz Pharmaceuticals' Leases (Quarter) stood at $86.6 million in 2021, then dropped by 15.31% to $73.3 million in 2022, then fell by 10.89% to $65.3 million in 2023, then dropped by 18.0% to $53.6 million in 2024, then grew by 14.22% to $61.2 million in 2025.
- Its Leases stands at $61.2 million for Q3 2025, versus $63.1 million for Q2 2025 and $49.2 million for Q1 2025.